Thallion Signs Letter of Intent With LFB Biotechnologies
Thallion Pharmaceuticals (Thallion) has signed a binding Letter of Intent (LOI) with LFB Biotechnologies (LFB) for the development of Shigamabs, Thallion’s product candidate for the treatment of Shiga
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.